Processing of meropenem sterile API for lyophilized intravenous presentations begins with a sterile batch that has passed sterility testing per USP <71> and bacterial endotoxin testing per USP <85>. The injectable formula is not a simple fill of API alone; the lyophilized cake is prepared by blending meropenem trihydrate equivalent to 1 g anhydrous meropenem with 90.2 mg anhydrous sodium carbonate for the 1 g vial presentation. This ratio is critical because the carbonate buffer shifts the reconstituted pH into the 7.3–8.3 range at 50 mg/mL, minimizing acid-catalyzed beta-lactam ring opening. The aseptic fill line operates under Grade A laminar airflow with Grade B background in accordance with EU GMP Annex 1, clause 4.4; filling needles of 0.8 mm to 1.2 mm internal diameter reduce shear and foaming during liquid filling. After filling, partially stoppered vials are transferred to a lyophilizer equipped with freeze-drying microscopy to determine collapse temperature, because published data for this exact meropenem/sodium carbonate cake configuration is limited. Primary drying is commonly executed at chamber pressure between 50 mTorr and 150 mTorr, with shelf temperature ramped from -40°C to +30°C over 36–48 h depending on condenser load and shelf area. On production lyophilizers with shelf areas above 10 m², edge vials dry faster than center vials; this creates cake moisture distribution and may require a secondary drying hold of at least 4 h after all thermocouples exceed ambient shelf set point. Residual moisture after cycle is controlled at ≤2.0% w/w, because higher residual water accelerates solid-state hydrolysis of the beta-lactam ring. After reconstitution with 20 mL Sterile Water for Injection, the 50 mg/mL solution is inspected per USP <790>; for infusion, dilution to 1–20 mg/mL in 0.9% sodium chloride is standard. Terminal steam sterilization is not applied because aqueous meropenem degrades at autoclave temperatures; aseptic filtration through 0.22 µm sterilizing filters is used before lyophilization. After dilution, osmolality in 0.9% sodium chloride remains within typical infusion-compatible limits and requires no further tonicity adjustment for peripheral administration.

What Controls the Reconstitution Time of Meropenem Powder for Injection?

Reconstitution time in dry-powder vials is controlled by the surface area of the powdered cake, the residual headspace vacuum, and the temperature of the diluent. The 500 mg and 1 g presentations are blended with sodium carbonate to prevent agglomeration and to generate a pH that supports rapid dissolution. In an unvented vial, the negative pressure is a critical process parameter; if the vacuum is lost through closure deformation or a pinhole leak, the time to fully wet the powder increases because air pockets become entrained in the powder bed. Conditioning the diluent to 20–25°C reduces reconstitution time to below 2 minutes for intact vials, whereas diluent stored at 2–8°C can extend the wetting phase and produce visible aggregates. The powder blend is filled by weight with in-process check weights at 100%; fill volume tolerances are tighter than ±2% to maintain both dosage accuracy and headspace vacuum. The stoppers are fluoropolymer-coated butyl rubber to limit extractables; after steam sterilization the stoppers are dried to ≤0.5% moisture. The reconstituted vial must be visually inspected and then transferred to an infusion container within the validated in-use hold time. Holding a 50 mg/mL solution at 25°C for longer than the approved in-use period causes pH drift due to bicarbonate formation and beta-lactam hydrolysis; this is the main operational boundary in hospital compounding areas.

In elastomeric infusion devices used for outpatient parenteral antimicrobial therapy, meropenem is prepared at 20 mg/mL in 0.9% sodium chloride and filled into a silicone-bladder elastomeric pump in an ISO Class 7 cleanroom conforming to ISO 14644-1:2015. The solution is stable only within a narrow thermal window: at 25°C the in-use hold time is limited to 8 hours, and at 2–8°C the hold time may extend to 24 hours, depending on the container material and the final concentration. Extended-infusion regimens of 3 hours or longer are used in severe infections to increase the fraction of time that free drug concentration exceeds the minimum inhibitory concentration; this alters the risk profile because the solution remains at room temperature during the entire administration period. The pump tubing is polyisoprene or polyvinyl chloride; PVC-free tubing is preferred because published extractables data for meropenem infusion in PVC containers is limited. The pH of the infusing solution is measured at the start and end of the administration; a drop below 5.0 indicates progressive degradation. Temperature excursions above 30°C invalidate the in-use period, and the pump reservoir should be protected with phase-change cooling packs. Visible precipitation or color change from pale yellow to yellow or amber signals that the solution has exceeded the safe use boundary and must be discarded.

Oral Tablet Development: Stability Constraints Imposed by Gastric Acid and Efflux Transport

A tablet core containing meropenem trihydrate without gastro-resistant protection is chemically unstable in the gastric environment because the beta-lactam ring is rapidly hydrolyzed at pH values below 4.0. In 0.1 M hydrochloric acid dissolution media, the unprotected active pharmaceutical ingredient degrades within the acid-stage duration specified for delayed-release testing in USP <711>. The second limitation is permeability: meropenem is a zwitterionic carbapenem with poor passive intestinal permeability, and therefore no globally registered oral tablet product based on meropenem free acid has been established in the main pharmacopoeias. Exploratory tablet prototypes have used anionic methacrylate copolymers as enteric coatings with a dissolution threshold at pH 5.5; the core is prepared by direct compression because wet granulation introduces water and heat that can destabilize the trihydrate. Tablet hardness is maintained at 8–12 kp, and friability is kept below 1.0% to prevent edge damage that would expose the core to gastric fluid. After coating, the delayed-release dissolution test is performed according to USP <711> Method A: 2 hours in 0.1 M hydrochloric acid followed by phosphate buffer at pH 6.8. In the acid stage, release should be ≤10% of labeled content; in the buffer stage, release should exceed 80% within 45 minutes for an exploratory formulation. The clinical translation of such a tablet is constrained by the absence of published bioequivalence or absolute bioavailability data, and manufacturers must not assume that enteric protection alone resolves the permeability problem.

When Meropenem Is Loaded into Enteric-Coated Pellet Capsules

Loading meropenem into enteric-coated pellets inside hard gelatin or hypromellose capsules shifts the formulation challenge from tablet compression to extrusion-spheronization and Wurster fluid-bed coating. The pellet core is produced by low-water extrusion-spheronization using microcrystalline cellulose and crospovidone; the extrudate is spheronized at a moisture level that does not exceed 10% w/w, and drying is carried out at inlet air temperature no higher than 40°C because the trihydrate form is thermally sensitive. The dried cores are screened to 0.8–1.2 mm pellet diameter to ensure reproducible capsule fill weight and enteric coating thickness. The enteric coating is applied in a Wurster coater with an inlet air temperature of 30–35°C, product temperature of 24–28°C, spray rate of 0.5–1.0 g/min/kg of cores, and atomization pressure of 1.5–2.0 bar. The coated pellets are filled into size 1 or size 0 capsules with a dosator or dosing-disc machine; fill weight is controlled by pellet bulk density, which typically ranges from 0.45–0.65 g/mL for immediate-release multiparticulate systems. Dissolution testing uses USP <711> delayed-release Method A; the acid-stage release must be ≤10% after 2 hours, and the buffer-stage release must reach ≥80% within 45 minutes at pH 6.8. The capsule shell moisture is kept below 5% w/w during storage to prevent pellet sticking. The principal operational boundary is that no approved oral capsule product exists; this route is limited to investigational use because the oral bioavailability of meropenem is not established.

Sachet-based granule formulations require an acid-neutralizing buffer system because the beta-lactam ring undergoes aqueous hydrolysis below pH 4.0. The dry granule blend is prepared by low-shear mixing with anhydrous sodium citrate or sodium bicarbonate to control the reconstituted suspension pH between 6.0 and 7.0. The granulation step is carried out in a fluid-bed dryer with inlet air dew point ≤0°C and product temperature ≤35°C to minimize water uptake and thermal dehydration of the trihydrate. Granules are sized between 20-mesh and 60-mesh sieves; the fine fraction below 60-mesh is re-granulated to avoid poor flow and segregation on the sachet fill line. Filling is performed on vertical form-fill-seal equipment in an environment with relative humidity ≤30%; the aluminum foil laminate has a water vapor transmission rate of ≤0.1 g/m²/24 h at 25°C and 75% RH when tested according to ASTM F1249. After reconstitution with water, the suspension must be assigned a chemical and microbial in-use hold time; published data for this specific configuration is limited, and a maximum of 7 days at 2–8°C is applied only if supported by a product-specific stability protocol. The pH should be re-checked at the time of each dose, and the preparation should be discarded if the pH falls below 5.0. Mixing with acidic fruit juice is incompatible because the pH shift accelerates beta-lactam hydrolysis. Since no globally approved oral granule monograph exists, release testing and clinical bridging data are the primary evidence required before such a sachet can be placed into commercial distribution.

Fixed-Dose Combination Injection with β-Lactamase Inhibitors

The fixed-dose combination of meropenem 1 g with vaborbactam 1 g is reconstituted with 20 mL of 0.9% sodium chloride for injection, giving 50 mg/mL of each active entity. The solution is then further diluted to 250 mL in 0.9% sodium chloride; dextrose-containing diluents are not used for this specific combination because published compatibility data for this configuration is limited. The infusion is administered over 3 hours to maintain the meropenem drug concentration above the minimum inhibitory concentration for extended intervals. In the compounding unit, the vaborbactam component does not alter the pH constraints of meropenem; the infusing solution should remain in the 6.0–8.0 pH range and must be visually inspected according to USP <790> before and after administration. The sterile API used in this combination must meet the same sterility and endotoxin controls as meropenem monotherapy; blending of the two sterile powders requires an aseptic environment with validated mixers that minimize shear and static electricity. The minimum fill weight of the combination vial is verified by in-process checkweighing at 100%; segregation of the two powders during blending is controlled by particle size overlap and geometric mixing, with a final blend uniformity acceptance of ≥95% label claim per USP <905> or equivalent. No terminal heat sterilization is applicable. The main operational boundary is the reconstituted and diluted solution hold time; at 25°C the infusion should follow the approved in-use period, and at 2–8°C the dilute solution may hold up to 24 hours if supported by the product-specific stability file. The combination is used in complicated urinary tract infections, including pyelonephritis; it is not interchangeable with meropenem monotherapy and must be prescribed on the basis of susceptibility testing.